**Compelling Investment Opportunity: Overweight Stance on Alexion Pharmaceuticals, Inc.**

**Executive Summary:**
Alexion Pharmaceuticals had a commendable performance in the third quarter, as evidenced by the robust growth metrics and strategic decisions that underscore the Company’s potential for sustained growth and profitability. While navigating some anticipated headwinds, the Company’s advancements in clinical trials, operational refinements, and strategic market expansions present compelling reasons to rate Alexion as an 'overweight' investment.

**Key Financial Performance Highlights:**
1. **Revenue Growth:**
   - **Total Revenue:** Increased by 8% year-over-year to $859 million, signaling strong market demand and effective business execution despite a 1% pricing headwind.
   - **Product Sales:** U.S., Europe, and Asia Pacific saw significant growth.
   - **Soliris Revenue**: Excluding the impact of ALXN1210 ordering patterns, Q3 volume growth was around 13%.

2. **Earnings Per Share:**
   - **Non-GAAP Earnings:** Increased by 17% to $1.44 per share, driven by robust revenue growth and favorable tax benefits following an IRS audit conclusion.

3. **Operational Efficiency:**
   - **Non-GAAP Operating Margin:** Remained impressive at 45%, benefiting from keen attention to managing operating expenses despite global expansions and increased R&D investments.

4. **Future Revenue Expectations:**
   - The Company raised the lower end of its full-year revenue forecast. This adjustment is emblematic of management's confidence in the continued robust sales performance of key products.
   - For 2018, despite anticipated headwinds from ongoing trials, Alexion is on track for sound revenue growth stemming from its robust product line and market expansions.

**Strategic Initiatives and Market Position:**
1. **Clinical Trials and Pipeline Development:**
   - Continued investment in ALXN1210 and its promising implications in the treatment portfolio underline Alexion's commitment to enhancing its market-leading position in rare diseases.
   - Introduction of new clinical studies in 2018, pointing towards a deliberate strategy to expand and diversify its product portfolio.

2. **Market Expansion:**
   - The introduction of new products in major markets (U.S., Germany, Japan), particularly with the planned MG launches, is expected to contribute positively to revenue streams in forthcoming quarters.

3. **Operational Restructuring:**
   - Alexion is underway with a strategic restructuring plan aimed at achieving a future operating margin of 50% by 2019, indicative of anticipated efficiency gains and cost management.

4. **Leadership in Rare Diseases:**
   - With the hire of Dr. Aradhana Sarin as SVP of Business Development and Corporate Strategy, Alexion is poised to further cement its authority in the rare disease market through strategic alliances and innovative developments.

**Investment Thesis:**
Given Alexion’s consistent performance, strategic growth initiatives, and strong pipeline developments, we advocate an 'overweight' investment stance. The Company's ability to navigate market complexities, coupled with a proactive approach to growth and innovation, makes it a valuable addition to investment portfolios seeking growth and stability in the biopharmaceutical sector.

**Recommendation:**
Investors should consider increasing their stake in Alexion Pharmaceuticals, leveraging the Company's promising outlook and strategic positioning to capitalize on growth opportunities in the evolving biopharmaceutical landscape.